Sensitivity vs Specificity: How Pharmacists Should Interpret Diagnostic Tests

Mohamad-Ali Salloum, PharmD • May 1, 2026

Share

  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button

Diagnostic tests shape almost every clinical decision pharmacists are involved in. From starting or stopping therapy to counseling patients who are confused by their results, pharmacists are often asked the same unspoken question:

“How much should I trust this test result for this patient?”

To answer that question confidently, pharmacists must understand two fundamental concepts: sensitivity and specificity.


🔬 What is a diagnostic test really doing?

Every diagnostic test attempts one thing: to separate people into two groups:

  • ✅ Those who truly have the disease
  • ✅ Those who truly do not have it

Because no test is perfect, mistakes occur:

  • False negatives: disease is present, but the test is negative
  • False positives: disease is absent, but the test is positive

Sensitivity and specificity describe how often these mistakes happen.


🎯 Sensitivity: Can this test find disease?

Sensitivity is the proportion of people who truly have the disease and test positive.

In plain terms:
If your patient really has the disease, how likely is this test to catch it?

A highly sensitive test produces very few false negatives.

Clinical memory trick:
SNOUTSensitive test + Negative result rules OUT disease

Clinical example: D‑dimer and pulmonary embolism

  • D‑dimer is highly sensitive for venous thromboembolism
  • A normal D‑dimer in a low‑risk patient essentially rules out PE
  • A positive result does not confirm PE

Pharmacist insight: A negative result explains why anticoagulation or imaging was avoided, while a positive result simply signals the need for further evaluation.


🎯 Specificity: Can this test exclude disease?

Specificity is the proportion of people without the disease who test negative.

In plain terms:
If the patient is healthy, how likely is this test to stay negative?

A highly specific test produces very few false positives.

Clinical memory trick:
SPINSpecific test + Positive result rules IN disease

Clinical example: Cardiac troponin

  • Troponins are highly specific for myocardial injury
  • A positive troponin strongly suggests true cardiac damage
  • Early negative results do not fully exclude MI

Pharmacist insight: This explains why antiplatelets and anticoagulants are escalated rapidly when troponin rises.


⚖️ Sensitivity vs specificity: the unavoidable trade‑off

Increasing sensitivity usually lowers specificity, and vice versa.

  • High sensitivity → fewer missed cases, more false alarms
  • High specificity → fewer false alarms, greater risk of missing disease

Example: COVID‑19 testing

  • Rapid antigen tests: lower sensitivity, high specificity
  • PCR tests: extremely sensitive but detect low‑level viral remnants

Pharmacist role: Explaining why a symptomatic patient may still need PCR despite a negative rapid test.


🧠 The most misunderstood concept: pretest probability

A test result never stands alone.

Pretest probability asks:
How likely was disease before the test was done?

The same result means different things depending on symptoms, risk factors, and clinical context.

Example: Troponin in two patients

  • Patient A: classic chest pain, multiple risk factors
  • Patient B: atypical symptoms, no risk factors

The identical troponin value can imply dramatically different realities.


📊 Predictive values: what patients actually care about

Positive Predictive Value (PPV): If the test is positive, how likely is disease actually present?

Negative Predictive Value (NPV): If the test is negative, how likely is disease truly absent?

Key pharmacist insight:
Predictive values change with disease prevalence.

This explains why screening tests behave differently in low‑risk versus high‑risk populations.


🧪 Screening vs confirmatory tests

  • Screening tests: prioritize sensitivity, accept false positives
  • Confirmatory tests: prioritize specificity, reduce misdiagnosis

Pharmacist responsibility: Preventing treatment decisions based on screening tests alone.


❌ Common interpretation pitfalls

  • Treating lab values instead of patients
  • Ignoring test timing
  • Assuming a normal result rules out disease
  • Forgetting disease prevalence

✅ Quick Knowledge Check

Test yourself: select the best answer for each question.

1. A highly sensitive test with a negative result is best used to:

Rule out disease
Confirm disease

2. Which test result is most affected by disease prevalence?

Sensitivity
Predictive values

3. A positive result from a highly specific test generally:

Strongly suggests true disease
Rules out disease


Final thought:
Diagnostic tests do not replace clinical judgment—they refine it. Pharmacists who understand sensitivity, specificity, and predictive values dramatically improve medication safety and patient care.


References:

  1. Fletcher RH, Fletcher SW, Fletcher GS. Clinical Epidemiology: The Essentials. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2014. 
  2. Altman DG, Bland JM. Diagnostic tests 1: Sensitivity and specificity. BMJ. 1994;308(6943):1552. 
  3. Altman DG, Bland JM. Diagnostic tests 2: Predictive values. BMJ. 1994;309(6947):102. 
  4. Jaeschke R, Guyatt G, Sackett DL. Users’ guides to the medical literature. III. How to use an article about a diagnostic test. JAMA. 1994;271(5):389–91. 
  5. Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: An updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527. 
  6. Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D‑dimer cutoff levels to rule out pulmonary embolism. N Engl J Med. 2014;370:1114–23. 
  7. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction. Eur Heart J. 2019;40(3):237–69. 


List of Services

    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button

    ABOUT THE AUTHOR

    Mohamad-Ali Salloum, PharmD

    Mohamad Ali Salloum LinkedIn Profile

    Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.

    Share

    Recent articles:

    By Mohamad-Ali Salloum, PharmD May 21, 2026
    Discover the best ways to learn new skills
    By Mohamad-Ali Salloum, PharmD May 19, 2026
    Stuck in your head? Discover why overthinking feels productive, how it sabotages your performance, and simple ways to shift into real action.
    By Mohamad-Ali Salloum, PharmD May 17, 2026
    References: Wood W, Quinn JM, Kashy DA. Habits in everyday life: Thought, emotion, and action. J Pers Soc Psychol . 2002;83(6):1281–1297. Wood W, Neal DT. The habitual consumer. J Consum Psychol . 2009;19(4):579–592. Neal DT, Wood W, Labrecque JS, Lally P. How do habits guide behavior? Perceived and actual triggers of habits in daily life. J Exp Soc Psychol . 2012;48(2):492–498. Wood W, Mazar A, Neal DT. Habits and goals in human behavior: Separate but interacting systems. Perspect Psychol Sci . 2021;16(1):1–16. Graybiel AM. Habits, rituals, and the evaluative brain. Annu Rev Neurosci . 2008;31:359–387. Smith KS, Graybiel AM. Habit formation. Dialogues Clin Neurosci . 2016;18(1):33–43. Yin HH, Knowlton BJ. The role of the basal ganglia in habit formation. Nat Rev Neurosci . 2006;7(6):464–476. Graybiel AM. The basal ganglia and chunking of action repertoires. Neurobiol Learn Mem . 1998;70(1–2):119–136. Schultz W. Dopamine reward prediction error coding. Dialogues Clin Neurosci . 2016;18(1):23–32. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science . 1997;275(5306):1593–1599. Nasser HM, Calu DJ, Schoenbaum G, Sharpe MJ. The dopamine prediction error: Contributions to associative models of reward learning. Front Psychol . 2017;8:244. Kahnt T, Schoenbaum G. The curious case of dopaminergic prediction errors and learning associative information beyond value. Nat Rev Neurosci . 2025;26:169–178. Lally P, van Jaarsveld CHM, Potts HWW, Wardle J. How are habits formed: Modelling habit formation in the real world. Eur J Soc Psychol . 2010;40(6):998–1009. American Psychological Association. Harnessing the power of habits. Monitor Psychol . 2020;51(8):78–83.
    By Mohamad-Ali Salloum, PharmD May 15, 2026
    References: Baddeley A. Working memory: theories, models, and controversies. Annu Rev Psychol . 2012;63:1–29. Chai WJ, Abd Hamid AI, Malin Abdullah J. Working memory from the psychological and neurosciences perspectives: a review. Front Psychol . 2018;9:401. Rogers RD, Monsell S. Costs of a predictable switch between simple cognitive tasks. J Exp Psychol Gen . 1995;124(2):207–231. Rubinstein JS, Meyer DE, Evans JE. Executive control of cognitive processes in task switching. J Exp Psychol Hum Percept Perform . 2001;27(4):763–797. Garner KG, Dux PE. Knowledge generalization and the costs of multitasking. Nat Rev Neurosci . 2023;24:98–112. Zhou X, Lei X. Wandering minds with wandering brain networks. Neurosci Bull . 2018;34(6):1017–1028. Sorella S, Crescentini C, Matiz A, et al. Resting‑state default mode network variability predicts spontaneous mind‑wandering. Front Hum Neurosci . 2025;19:1515902. Sweller J. Cognitive load during problem solving: effects on learning. Cogn Sci . 1988;12(2):257–285. 
    By Mohamad-Ali Salloum, PharmD May 13, 2026
    Why do we procrastinate even when tasks matter most? Discover the emotional roots of procrastination and how to stop
    By Mohamad-Ali Salloum, PharmD May 11, 2026
    Confidence and self-esteem are often confused but are psychologically distinct. Learn how they differ, how each develops, and why understanding both matters for real growth.
    By Mohamad-Ali Salloum, PharmD May 9, 2026
    Confidence isn’t about eliminating fear—it’s about acting despite it. Discover how courage, discomfort, and psychological growth build real confidence over time.
    By Mohamad-Ali Salloum, PharmD May 7, 2026
    References: McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med . 2014;371(11):993–1004. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med . 2007;357:2109–2122. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med . 2008;358:1431–1443. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med . 2008;358:2545–2559. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med . 1991;324:781–788. Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on cardiovascular and renal outcomes. N Engl J Med . 2020;383:1413–1424. Ioannidis JPA. Surrogate endpoints in clinical trials: are we being misled? BMJ . 2013;346:f314.
    By Mohamad-Ali Salloum, PharmD May 4, 2026
    References: Wager TD, Atlas LY. The neuroscience of placebo effects: connecting context, learning and health. Nat Rev Neurosci . 2015;16(7):403‑18. Frisaldi E, Shaibani A, Benedetti F, Pagnini F. Placebo and nocebo effects associated with pharmacological interventions: an umbrella review. BMJ Open . 2023;13:e077243. Colloca L, Finniss D. Nocebo effects, patient‑clinician communication, and therapeutic outcomes. JAMA . 2012;307(6):567‑8. Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a blinded, randomized trial of statin, placebo, and no treatment. N Engl J Med . 2021;385(23):2180‑9. Penson PE, Mancini GBJ, Toth PP, et al. Introducing the “drucebo” effect in statin therapy. J Cachexia Sarcopenia Muscle . 2018;9(6):1023‑33. Barnes K, Faasse K, Geers AL, et al. Can positive framing reduce nocebo side effects? Front Pharmacol . 2019;10:167. Caliskan EB, Bingel U, Kunkel A. Translating knowledge on placebo and nocebo effects into clinical practice. Pain Rep . 2024;9(2):e1142. von Wernsdorff M, Loef M, Tuschen‑Caffier B, Schmidt S. Effects of open‑label placebos in clinical trials: a systematic review and meta‑analysis. Sci Rep . 2021;11:3855.
    By Mohamad-Ali Salloum, PharmD May 4, 2026
    References: Zaniletti I, Larson DR, Lewallen DG, Berry DJ, Maradit Kremers H. How to distinguish correlation from causation in orthopaedic research. J Arthroplasty. 2023;38(4):634–637. Rush J, Ajami M, Look KA, Margolis A. Statistics review part 10: causality and confounding. J Pharm Soc Wis. 2014;17(1):45–52. Koopmans E, Schiller C. Understanding causation in healthcare: an introduction to critical realism. Qual Health Res. 2022;32(8–9):1207–1214. Kahlert J, Gribsholt SB, Gammelager H, Dekkers OM, Luta G. Control of confounding in the analysis phase – an overview for clinicians. Clin Epidemiol. 2017;9:195–204. Shi AX, Zivich PN, Chu H. A comprehensive review and tutorial on confounding adjustment methods for estimating treatment effects using observational data. Appl Sci (Basel). 2024;14(9):3662. Gao Y, Xiang L, Yi H, Song J, Sun D, Xu B, et al. Confounder adjustment in observational studies investigating multiple risk factors: a methodological study. BMC Med. 2025;23:132. Ho FK, Brown J, Galwey NW. Regression adjustment for causal inference. BMJ Med. 2025;4:e000816. Correia LCL, Mascarenhas RF, Menezes FSC, Oliveira Junior JS, Vaccarino V, Ross JS, et al. Confounder selection in observational studies in high‑impact medical and epidemiological journals. JAMA Netw Open. 2025;8(7):e2524176.
    More Posts